Sana Biotechnology

H.C. Wainwright analyst raised Sana Biotechnology's price target to $11, citing positive Phase 1 study results for T1D treatment without immunosuppression. SANA's stock, trading at $5.66, shows promise with stable C-peptide levels in trials, despite being overvalued. Leadership changes and analyst upgrades reflect optimism in Sana's innovative approach.

Sana Biotechnology's stock surged nearly 250% after reporting successful implantation of its islet cell therapy in a Type 1 diabetes patient without immunosuppression. eBay's stock rose 12% as Meta agreed to feature eBay listings on Facebook Marketplace in the U.S., Germany, and France, following EU antitrust concerns.

Sana Biotechnology's stock surged with a 249% increase in trading volume after HC Wainwright raised its price target to $11.00, maintaining a buy rating. The stock, last traded at $5.63, saw mixed analyst ratings but holds a 'Moderate Buy' consensus with a $14.25 average target. Institutional investors increased their stakes, with 88.23% ownership. The company reported a slight earnings beat and focuses on engineered cell medicines for unmet therapeutic needs.

Sana Biotechnology's shares surged 333% to $7.17 after announcing positive clinical trial results for a Type 1 diabetes treatment.

JMP Securities analyst Reni Benjamin rates Sana Biotechnology (SANA) as Hold, with shares at $1.75. Benjamin, with a -13.3% average return, covers healthcare stocks. SANA has a Moderate Buy consensus, $10.50 target, and trades between $1.52 and $12.00 over the past year.

Galapagos NV splits into two, focusing on oncology and transactions. Sana, Jasper, and Viking report early data and study starts. Pharma faces a patent cliff, prompting M&A. FDA's Califf expresses concerns over Trump's impact. Tenvie Therapeutics launches with $200M for neuroscience. Medicare may negotiate lower Ozempic prices. East Asians are underrepresented in biopharma leadership.

Sana Biotechnology's stock surged up to 400% after announcing a breakthrough in type-1 diabetes treatment, involving a successful allogeneic islet cell transplant without immunosuppression. The study showed functional pancreatic beta cells and insulin secretion, with no safety issues. TD Cowen upgraded SANA to Buy, citing reduced risk and potential for transformation in diabetes treatment.

TD Cowen upgraded Sana Biotechnology (NASDAQ:SANA) to buy, contrasting JMP Securities' downgrade to market perform. HC Wainwright maintained a buy rating with an $8 target. SANA shares rose to $4.49, with a $1B market cap. Analysts predict -1.16 EPS for the fiscal year. Institutional investors increased holdings, with 88.23% owned by them. Sana focuses on engineered cell medicines for unmet therapeutic needs.

2024 was a challenging year for the biopharma industry, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds to thousands of jobs. Cassava Sciences announced layoffs of 10 employees, 33% of its workforce, following a failed Phase III trial for its Alzheimer's drug. CytomX Therapeutics cut 40% of its staff to focus on clinical programs. Velia, a San Diego biotech, is shutting down, affecting 47 employees. Regeneron's acquisition of Oxular led to layoffs, with no Oxular employees joining Regeneron. Javara, Ring Therapeutics, Outlook Therapeutics, Editas, Bavarian Nordic, BenevolentAI, Chroma Medicine and Nvelop Therapeutics, Cellectar Biosciences, Carisma Therapeutics, Belharra Therapeutics, National Resilience, AmplifyBio, Agenus, Alligator Bioscience, Idorsia Pharmaceuticals, Kronos Bio, Novartis, Recursion Therapeutics, Medigene, Alector, Bristol Myers Squibb, Sonata Therapeutics, 23andMe, Johnson & Johnson, Merck, Gilead Sciences, Adaptimmune, Sensei Biotherapeutics, Marinus Pharmaceuticals, Orna Therapeutics, Thermo Fisher Scientific, Charles River Laboratories, Aurinia Pharmaceuticals, Viracta Therapeutics, Astellas Gene Therapies, Sana Biotechnology, Sage Therapeutics, Compass Pathways, Spero Therapeutics, ICON, Pfizer, Takeda, SalioGen Therapeutics, Evonik, Medtronic, CareFusion Resources, Turnstone Biologics, Leo Pharma, Astellas Pharma, Prime Medicine, Kaléo, Stryker, Relay Therapeutics, ImmunityBio, Shattuck Labs, Inventprise, bluebird bio, Athira Pharma, AGC Biologics, Oncternal Therapeutics, Biosense Webster, Vesigen Therapeutics, Connect Biopharma, BioMarin, IN8bio, Edwards Lifesciences, DermTech, Repare Therapeutics, Genentech, Tome Biosciences, Aadi Bioscience, Lykos Therapeutics, Evotec, Galera Therapeutics, Grail, Ovid Therapeutics, Lexicon Pharmaceuticals, Acelyrin, Boundless Bio, FibroGen, Ajinomoto Bio-Pharma Services, AN2 Therapeutics, Entero Therapeutics, Precigen, Sumitomo Pharma America, uniQure, Vir Biotechnology, Arbutus Biopharma, HilleVax, and Bayer also announced significant layoffs, reflecting a tough year for the industry.

Sana Biotechnology's stock surged over 300% after announcing positive results from a Type 1 Diabetes treatment trial, showcasing successful islet cell engraftment and insulin production without immune response. Analysts maintain a Buy rating, highlighting the potential of Sana's hypoimmune platform to treat autoimmune diseases without long-term immunosuppression.